Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Di-O-methylfraxetin, chemically named 6,7,8-trimethoxy-1-benzopyran-2-one, is an important class of coumarin-derived compounds that have attracted widespread attention in the field of natural product pharmacology in recent years due to their unique chemical structure and significant biological activity. Coumarins are widely found in various plants and possess anti-inflammatory, antioxidant, antibacterial, and antitumor pharmacological activities. As one of the representative compounds, alkalogistin demonstrates its potential anti-tumor application value due to its excellent bioavailability and multi-target regulatory capabilities.

This review aims to systematically summarize the chemical structure and physicochemical properties of alkalin, its plant origins, and extraction methods, with a focus on evaluating its pharmacological activity and mechanism of action. By combining druggability evaluation and pharmacokinetic data, it explores its clinical application prospects and development trends, providing theoretical basis and directions for subsequent related research and new drug development.

Chemical structure and physicochemical properties

Ash glycerin (CAS No. 6035-49-0) belongs to the coumarin-class compounds, with a molecular formula C13H12O5 and a molecular weight of 236.2230. Its core structure is the 1-benzopyran-2-one backbone, with three methoxy groups located at positions 6, 7, and 8, giving it unique chemical properties. The rigidity of the benzopyran ring system and the electron supply effect of the methoxy group in the structure enable it to exhibit high affinity in intermolecular interactions and target binding.

In terms of physicochemical properties, the LogP value of alkalusin is 1.7108, indicating moderate lipid solubility, which helps with cell membrane penetration and distribution in the body. The polarized surface area (TPSA) is 57.9 Ų, indicating a certain polarity that facilitates hydrogen bonding and polar interactions with biological macromolecules. Its low water solubility (0.1699 mg/mL) suggests that its solubility in the body may exist, but moderate lipophilic solubility favors oral absorption. Its high blood-brain barrier penetration capability suggests its potential applications in central nervous system diseases. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames trial scored 0.9, indicating a low genotoxicity risk and good safety.

Plant Origins and Extraction Methods

Ash resin is mainly found in the ash tree (Fraxinus spp.) and related plants, especially its bark, leaves, and roots. As a secondary metabolite of coumarins, alkalashin participates in plant defense mechanisms and has antibacterial and insect-resistant effects.

Traditional extraction methods mostly use organic solvent extraction methods, such as methanol, ethanol, or ethyl acetate, combined with ultrasound-assisted extraction or reflux extraction technologies to improve extraction efficiency. The general steps include:

1. Plant raw materials are dried and crushed, then selected for suitable particle sizes.
2. Extraction is done with 70% ethanol or methanol, usually taking 1-3 hours.
3. Through purification steps such as filtrate concentration, liquid-liquid distribution, and silica gel column chromatography, the ash resin was isolated.
4. Finally, purity testing is performed using high-performance liquid chromatography (HPLC), with purity reaching over 95%.

In recent years, the application of supercritical CO2 extraction and molecular blotting technologies has provided new ideas for efficient extraction and purification of alkake, balancing environmental friendliness and economic benefits.

Pharmacological activity research

Ashokin exhibits significant pharmacological activity in various in vitro and in vivo models, with particularly abundant research results in the anti-tumor field. Its main pharmacological activities include:

Antitumor activity

Numerous studies have shown that inhibiting proliferation, inducing apoptosis, and suppressing metastasis in various tumor cell lines. Its anti-tumor effects involve multiple signaling pathways and molecular targets, covering key links such as cell cycle regulation, apoptosis signaling, cell migration, and invasion.

In various tumor models including breast, lung, liver, and colorectal cancers, alkalin exhibits significant cytotoxicity and anti-proliferative effects. The mechanism of tumor cell apoptosis induction mainly regulates the expression of BCL2 family proteins (such as MCL1 and BCL2), activating mitochondria-dependent apoptosis pathways. Additionally, alkalin can inhibit the STAT3 signaling pathway, blocking tumor cell proliferation and immune escape.

Antioxidant and anti-inflammatory activities

Alkalashin has strong antioxidant properties, scavenging free radicals and reducing cellular damage caused by oxidative stress. Its anti-inflammatory effect is achieved by inhibiting the release of inflammatory mediators and modulating the NF-κB signaling pathway, helping to alleviate chronic inflammation-related diseases.

Other activities

Some studies have also reported the potential effects of alkalin in neuroprotection, cardiovascular protection, and antibacterial effects, but the related mechanisms require further elucidation.

Mechanism of action and molecular targets

The multi-target action characteristics of chalcosin form the basis of its pharmacological diversity. Through molecular docking and biological experiment validation, its main targets have been confirmed to include:

• MCL1 (Myeloid cell leukemia 1) and BCL2 (B-cell lymphoma 2): As anti-apoptotic proteins, alkalashin promotes tumor cell apoptosis by downregulating its expression.
• STAT3 (Signal transducer and activator of transcription 3): Ash resin inhibits phosphorylation, blocking STAT3-mediated cell proliferation and immune regulation.
• MMP2 (Matrix metalloproteinase-2): By inhibiting MMP2 activity, it reduces stromal degradation in tumor cells and inhibits invasion and metastasis.
• TOP1 (Topoisomerase I) and TOP2A (Topoisomerase II alpha): interfere with DNA topoisomerase function, hindering DNA replication and repair in tumor cells.
• HIF1A (Hypoxia-inducible factor 1-alpha): Inhibits adaptive responses in hypoxic tumor environments, reducing angiogenesis and metabolic reprogramming.
• MAPK1 (Mitogen-activated protein kinase 1): regulates cell signaling and affects proliferation and apoptosis balance.
• ESR1 (Estrogen receptor alpha) and CYP19A1 (Aromatase): In hormone-dependent tumors, they regulate estrogen signaling pathways and inhibit tumor growth.

The synergistic regulation of these targets gives alkalashin broad-spectrum and multi-mechanism advantages in anti-tumor therapy, reducing the risk of drug resistance.

Druggability evaluation and pharmacokinetics

The druggability parameters of alkalashin indicate that it has good potential for drug development. The molecular weight of 236.2230 complies with the Lipinski rule, with a moderate LogP, which is beneficial for oral absorption and cell membrane penetration. The TPSA value is moderate, supporting effective binding to biological targets. Although water solubility is relatively low, it can be improved through formulation technology.

High blood-brain barrier penetration suggests that alkalose has potential application value in central nervous system diseases. hERG channel inhibition negative, reducing the risk of cardiotoxicity. Ames trial results showed that it carries a low genotoxicity risk and is relatively safe.

Pharmacokinetic studies show that alkalashin is rapidly absorbed orally and has a moderate plasma half-life, mainly metabolized by the liver. The metabolites still require further identification. Its bioavailability is limited by water solubility, and the development of delivery systems such as nanocarriers and liposomes is expected to enhance its in vivo exposure and efficacy.

Prospects and outlooks for clinical applications

As a natural product, alkalashin possesses multi-target, multi-mechanism anti-tumor activity, aligning with current trends in precision medicine and multi-target drug development. Its excellent safety and druggability lay the foundation for clinical translation. Future research should focus on:

1. In-depth mechanistic research: Through systems biology and multi-omics techniques, comprehensive analysis of the functional network and signaling pathways of alkalusin.
2. Pharmacokinetic and toxicological evaluation: Improving in vivo metabolic pathways and long-term toxicity data to ensure clinical safety.
3. Formulation optimization: Developing novel delivery systems to overcome water solubility and bioavailability limitations.
4. Preclinical and clinical trials: Conduct animal models and early-stage clinical trials to verify efficacy and safety.
5. Combination drug research: Explore synergistic effects with existing chemotherapy or targeted drugs to improve treatment outcomes and reduce the risk of resistance.

Additionally, given its ability to penetrate the blood-brain barrier, the potential of alkaserin in neurotumors and neurodegenerative diseases is also worth noting.

Conclusion

As a structurally unique coumarin-type natural product, alkalin shows broad prospects for drug development thanks to its multi-target antitumor activity and good druggability. Current research has preliminarily revealed its mechanism of action and pharmacological effects, but further systematic and in-depth research is needed, especially in pharmacokinetics, clinical translation, and formulation optimization. In the future, with the integration of multiple disciplines and the application of new technologies, alkaloidin is expected to become an innovative drug in the fields of anti-tumor and other major disease treatments, contributing significantly to the development of natural product pharmacology.